Full TitleA Pilot Study of Romosozumab Efficacy and Safety for the Management of Myeloma-related OsteoLytic Disease in Postmenopausal Women with Multiple Myeloma and Osteoporosis (REMOLD-MM)
Romosozumab is a drug used to treat postmenopausal people with osteoporosis who are at increased risk of bone fractures. It works to increase bone formation and decrease bone breakdown. In this study, researchers want to measure the effect of romosozumab on bone formation in postmenopausal people with multiple myeloma, myeloma-related bone disease, and osteoporosis. Romosozumab is given as an injection under the skin once a month.
Who Can Join
To be eligible for this study, patients must meet several requirements, including the following:
- Participants must be postmenopausal (had last menstrual cycle at least 12 months before entering the study) and have osteoporosis, multiple myeloma, and myeloma-related bone disease (lytic bone lesions seen on imaging).
- This study is for adults who were assigned female at birth.
For more information and to ask about eligibility for this study, please contact the office of Dr. Carlyn Tan at 646-608-3778.